Sage Therapeutics Stock Price - SAGE

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Sage Therapeutics Inc SAGE NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -3.86 -2.35% 160.48 167.765 155.99 163.65 164.34 16:01:00
Bid Price Ask Price Spread Spread % News
155.50 168.00 12.50 7.44% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
4,995 282,128 $ 160.48 $ 45,275,399 372,392 79.88 - 193.56
Last Trade Time Type Quantity Stock Price Currency
16:13:53 priorref 5,262 $ 160.49 USD

Sage Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 8.29B 51.66M $ -372.88M -8.07 - 50.81M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Sage Therapeutics News

Loading Messages....

Latest SAGE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SAGE Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week152.09167.82152161.9238279k8.395.52%
1 Month166.3173.755146.67162.0753372k-5.82-3.50%
3 Months179.74193.56146.67169.0071367k-19.26-10.72%
6 Months158.8193.56146.67167.9458409k1.681.06%
1 Year145.57193.5679.88146.2760472k14.9110.24%
3 Years44.12195.9738.3117.8007517k116.36263.74%
5 Years27.02195.9726.280192.6746472k133.46493.93%

Sage Therapeutics Description

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.

Your Recent History
Sage Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.